Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants.
Jennifer E HibmaMelissa O'GormanSunil NepalSylvester PawlakKatherine GinmanYazdi K PithavalaPublished in: Cancer chemotherapy and pharmacology (2021)
Both oral and IV lorlatinib were well-tolerated in healthy participants and oral lorlatinib is highly bioavailable after oral administration.